Zai Lab’s Zoci Wins U.S. FDA Fast Track Designation for Aggressive Rare Cancer (epNECs)
Zai Lab’s drug Zoci got FDA Fast Track for rare cancer epNEC, showing 38% tumor response in early trials, speeding approval path.
/ 111 items
#XY Event-Driven Stocks↓
INBRX-106 + Keytruda Nearly Doubles Response Rate in First-Line Head & Neck Cancer
Inhibrx drug INBRX-106 with pembrolizumab boosted tumor response in head/neck cancer, showing higher shrinkage and immune activation.
Erasca Jumps on Merck Collaboration for RAS-Mutant Cancer Combo Trial
Erasca rises after teaming with Merck to test ERAS-0015 + Keytruda in RAS cancers, showing early tumor shrink but past safety concern.
MoonLake Gets Major Analyst Boost After “Best-in-Class” FDA Meeting
MoonLake gets FDA support for its HS drug, showing top results. Analysts stay bullish with strong growth potential ahead.
Atara Biotherapeutics Stock Soars After FDA Green Light for Cancer Therapy
Atara stock jumps 52% after FDA signals its cancer therapy may get approved, boosting hope for patients and investors.
Angelini Pharma Buys US Catalyst for $4.1 Billion in State-Backed Deal
Angelini is set to buy US-based Catalyst for $31.50 per share in a state-backed deal, expanding into rare neurological diseases and entering the US market.